<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="46237">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02504307</url>
  </required_header>
  <id_info>
    <org_study_id>Laranjeiras</org_study_id>
    <nct_id>NCT02504307</nct_id>
  </id_info>
  <brief_title>OCT Evaluation 3 Months After Sirolimus Eluting Stent Implantation</brief_title>
  <acronym>Laranjeiras</acronym>
  <official_title>Randomized Evaluation of Vascular Healing After Implantation of Sirolimus Eluting Stent Inspironâ„¢ Versus Its Own Bare Metal Version- An OCT Evaluation After 3 Months Follow-up</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Scitech Produtos Medicos Ltda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Scitech Produtos Medicos Ltda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, single center, randomized and non-inferiority study, to include up to 60
      patients with de novo coronary artery disease. Patients will be followed at 30 days, 3, 6
      and 12 months. At 3 months all patients will be submitted to angiographic and OCT
      evaluation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>3 months</time_frame>
    <description>Percentage of strut coverage by OCT</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Inspiron</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sirolimus Eluting Stent Inspiron</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cronus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bare Metal Stent</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sirolimus Eluting Stent Inspiron</intervention_name>
    <description>Angioplasty with Sirolimus Eluting Stent Inspiron implantation</description>
    <arm_group_label>Inspiron</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Bare Metal Stent</intervention_name>
    <description>Angioplasty with Bare Metal Stent Cronus implantation</description>
    <arm_group_label>Cronus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  one or two de novo lesions (&gt; 50% visual estimation)

          -  lesion diameter between 2.5 and 3.5 mm

          -  lesion length up to 33 mm.

        Exclusion Criteria:

          -  MI within the last 72 hours

          -  restenotic lesion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sergio Leandro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Insituto Nacional de Cardiologia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sergio Leandro</last_name>
    <phone>55(21)986261000</phone>
    <email>sergiom.leandro@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Instituto Nacional de Cardiologia</name>
      <address>
        <city>Rio de Janeiro</city>
        <state>RJ</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sergio Leandro</last_name>
    </contact>
    <investigator>
      <last_name>Sergio Leandro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <lastchanged_date>April 12, 2016</lastchanged_date>
  <firstreceived_date>July 20, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
